Shots:

• GSK will initiate a clinical trial to evaluate its RA drug- otilimab on patients suffering from pneumonia related to COVID-19 at the end of May’2020. The study will evaluate the efficacy and safety of otilimab (IV) vs PBO in addition to SOC in ~800 patients with severe COVID-19 related pulmonary disease
• The company anticipates the initial clinical results of the study by the end of 2020. If the results are positive- the company will work with regulatory bodies to make it available to the patients as soon as possible
• Otilimab is a mAb targeting GM-CSF and acts by blocking the interaction of GM-CSF with its cell surface receptor and entered in a P-III study for RA last year and was originally developed by MorphoSys. In 2013- Morphosys granted rights for the therapy to GSK

Click here ­to­ read full press release/ article 

 Ref: Clinical Trial. gov | Image: GSK